Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 19.61 | -0.07 | -1.00 | -4.61 |
| FCF Yield | -0.16% | -0.62% | -1.06% | -0.43% |
| EV / EBITDA | -413.44 | -136.33 | -70.16 | -144.72 |
| Quality | ||||
| ROIC | -5.73% | -10.71% | -9.23% | -7.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.65 | 0.94 | 0.84 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 29.86% | -22.23% | -39.91% | 11.37% |
| Safety | ||||
| Net Debt / EBITDA | 8.98 | 1.48 | 1.85 | 2.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |